Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JQHJW
ADC Name
AGX101
Synonyms
AGX 101; AGX-101; Anti-TM4SF1 ADC (Angiex)
   Click to Show/Hide
Organization
Angiex, Inc.
Drug Status
Phase 1
Indication
In total 3 Indication(s)
Breast ductal carcinoma [ICD11:2C61]
Phase 1
Lung cancer [ICD11:2C25]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
Drug-to-Antibody Ratio
2
Antibody Name
Undisclosed
Antigen Name
Transmembrane 4 L6 family member 1 (TM4SF1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 92.6
%
MIA PaCa-2 cells
Pancreatic ductal adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 93.4
%
MIA PaCa-2 cells
Pancreatic ductal adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 94.5
%
SK-BR-3 cells
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 95.6
%
HCC1954 cells
Breast ductal carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 98.1
%
Calu-3 cells
Lung adenocarcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.02
nM
A-549 cells
Lung adenocarcinoma
Half Maximal Effective Concentration (EC50) 
0.02
nM
MIA PaCa-2 cells
Pancreatic ductal adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 92.60% (Day 28) High TM4SF1 expression (TM4SF1+++)
Method Description
Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model Pancreatic cancer CDX model
In Vitro Model Pancreatic ductal adenocarcinoma MIA PaCa-2 cells CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 93.40% (Day 23) High TM4SF1 expression (TM4SF1+++)
Method Description
Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model Pancreatic cancer CDX model
In Vitro Model Pancreatic ductal adenocarcinoma MIA PaCa-2 cells CVCL_0428
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 94.50% (Day 23) High TM4SF1 expression (TM4SF1+++)
Method Description
Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model Breast ductal cancer CDX model
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.60% (Day 33) High TM4SF1 expression (TM4SF1+++)
Method Description
Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model Breast ductal cancer CDX model
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.10% (Day 23) High TM4SF1 expression (TM4SF1+++)
Method Description
Mice bearingeither CALU-3 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
In Vivo Model Lung adenocarcinoma CDX model
In Vitro Model Lung adenocarcinoma Calu-3 cells CVCL_0609
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.02 nM High TM4SF1 expression (TM4SF1+++)
Method Description
The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ cell lines.
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.02 nM High TM4SF1 expression (TM4SF1+++)
Method Description
The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ solid tumor cell lines.
In Vitro Model Pancreatic ductal adenocarcinoma MIA PaCa-2 cells CVCL_0428
References
Ref 1 AGX101- A novel TM4SF1-directed ADC for the treatment of solid tumors; 2022.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.